Taking AIM1 at prostate cancer invasion and metastasis

Progression to metastatic disease is the major cause of prostate cancer related death. Loss or mislocalization of AIM1 (aka CRYBG1), which regulates cytoskeletal remodeling, was shown to promote prostate cancer invasion and metastases. Read more about it in Haffner et al, Nat Commun, 2017. See also the press release and some of the media coverage of the findings.

Heart drug found to have activity in prostate cancer

Our multidisciplinary team used both laboratory and epidemiological approaches to uncover a potential application of the heart drug digoxin in prostate cancer prevention and/or therapy. Read about it in the April issue of Cancer Discovery. This work has been covered by several press sources, e.g., ScienceDaily (Apr. 3, 2011): Heart Drug Cuts Prostate Cancer Risk, Holds Potential for Therapeutic Use.

Hydroxymethylcytosine in normal and cancer tissues

Our research team recently showed that 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments in normal tissues and profoundly reduced in multiple human cancers. These findings were published in the August 2011 issue of Oncotarget, and has been covered by multiple independent epigenetics blogs including the

Srinivasan (Vasan) Yegnasubramanian, M.D., Ph.D.
Assistant Professor of Oncology
Johns Hopkins University

Sidney Kimmel Comprehensive Cancer Center
Cancer Research Building II, Room 145
1550 Orleans Street
Baltimore, MD, 21231